Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients

Launched by OWLSTONE LTD · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain chemicals found in breath, known as volatile organic compounds (VOCs), can help doctors detect a serious fungal infection called invasive aspergillosis (IA) in patients who have received lung transplants. The researchers believe that measuring these compounds could provide a new way to diagnose this infection early, which is important for effective treatment.

To participate in the study, patients must be over 18 years old, have received a lung transplant, and be suspected of having an invasive fungal disease. They must also be able to provide breath samples and consent to join the trial. However, certain patients will not be eligible, such as those on mechanical ventilation or those who have been diagnosed with other respiratory infections recently. If you join, you will provide breath samples at appointments, and the study aims to see how well these samples can help identify IA. Your participation could contribute to better understanding and diagnosis of fungal infections in lung transplant recipients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria: Patients with the following criteria will be included in the study:
• • 1. Over the age of 18 years
• • 2. Recipient of single/double lung transplant
• • 3. Willingness to participate in the study
• • 4. Suspected of invasive fungal disease or undergo surveillance appointments
• • 5. Capable of providing sample
• • 6. Capable of providing consent
• • -
• Exclusion Criteria: Patients with the following criteria will be excluded from the study:
• • 1. On mechanical ventilation, oxygen supplementation including nasal cannula; simple, fixed, or non-rebreathing face mask at presentation.
• • 2. Admitted to the intensive care unit at presentation.
• • 3. The subject is currently diagnosed with a confirmed bacterial or viral respiratory infection or has received a diagnosis of a respiratory viral or bacterial infection within the last 4 weeks.
• • 4. Previous diagnosis of Cystic Fibrosis
• • 5. Use of antifungals in previous 4 weeks
• • 6. Has been previously diagnosed with respiratory fungal infection other than aspergillus within the last 3 months upon presentation.
• • 7. Declines participation in the study.
• • 8. On mold antifungal for \>72 hours.
• • -